Lipella Pharmaceuticals Inc.

What they do

Lipella reformulates existing generic active agents using its metastable liposome drug delivery platform to develop new therapies. Its lead candidates are LP-10 for radiation-induced hemorrhagic cystitis and LP-310 for oral lichen planus, both based on tacrolimus. The company is also evaluating LP-410 and LP-50, but no products are commercialized and revenue from sales is not expected for several years.

Revenue drivers

• No product candidates commercialized — Revenue consists solely of grant revenue and other non-product income; 2024 annual revenue was $536,357, reflecting no commercial sales.
• LP-10 (Hemorrhagic cystitis) — Phase 2a trial completed in 2023; no revenue generated yet, but potential future milestone or royalty payments if approved.
• LP-310 (Oral lichen planus) — Preclinical/early stage; no revenue, but represents a second potential market opportunity.

Recent performance

For Q3 2025 (quarter ended September 30, 2025), revenue was $86,727, down from $129,390 in Q2 2025 and $80,380 in Q4 2024; the company reported a net loss of $5.0 million for 2024, deepening from $4.6 million in 2023. Operating cash outflows were $4.0 million in 2024 versus $3.2 million in 2023. As of September 30, 2025, cash and equivalents were $1.9 million, total assets were $2.3 million, and shareholder equity was $1.5 million.

Strategy

Management intends to continue developing LP-10 and LP-310 through clinical trials, leveraging the FDA orphan drug designation for LP-10 and seeking additional regulatory designations. The company plans to apply for more designations if phase 2a results are qualifying. It also aims to protect its intellectual property through patents expiring between 2034 and 2035, and may pursue market data exclusivity. The strategy includes raising additional capital to fund operations, as the company acknowledges its products are early-stage and approval is uncertain.

Risks

• Going concern risk — The company has incurred net losses since inception and expects continued losses, with insufficient capital to fund operations without additional financing.
• Clinical and regulatory uncertainty — LP-10 is in early-stage clinical trials (phase 2a), and there is no guarantee of successful progression or FDA approval for any candidate.
• Dependence on lead candidates — The business is substantially dependent on LP-10 and LP-310, and any delays or failure would harm the company.
• Funding and liquidity risk — Raising capital is difficult as a company trading on OTC markets, and failure to raise funds may force curtailment or cessation of operations.

Outlook

Management expects to continue incurring operating losses and will need to raise additional funding. The near-term focus is on advancing LP-10, with plans to apply for additional regulatory designations if phase 2a results are positive. The company also faces the risk of needing to raise capital under tight credit conditions and the possibility of relisting on a national exchange.